Search
Search Results
##search.searchResults.foundPlural##
-
THE BIOLOGY OF MYCOBACTERIUM TUBERCULOSIS INFECTION.
10549PDF: 6330HTML: 21779 -
NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE Guest Editor: Raffaella Origa
6794PDF: 3638HTML: 750 -
PARASITIC INFECTIONS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
3673PDF: 1233HTML: 3880Untitled: 207Untitled: 257 -
Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia
2907PDF: 682HTML: 1932figure 1: 167figure 2: 176 -
TREATMENT OF EARLY STAGES HODGKIN LYMPHOMA DURING PREGNANCY
3542PDF: 1063HTML: 873 -
COULD PLASMA GLUCOSE (PG) INCREMENT (PG %) EXPAND THE CLINICAL WEIGHT OF OGTT? PRELIMINARY FINDINGS IN 19 TDT PATIENTS (Β-TDT) WITH NORMAL GLUCOSE TOLERANCE Plasma glucose (PG) increment (PG %) and pancretic β-cell dysfunction in thalassemia
698PDF: 489HTML: 39 -
HIGHLIGHTS ON THE CONTRIBUTION OF GUT MICROBIOTA TO IMMUNE-MEDIATED DISEASES IN CHILDHOOD Gut microbiota in childhood immune-mediated diseases
1008PDF: 605HTML: 73 -
DNA Repair Genes and Chronic Myeloid Leukemia: XPD (751), XRCC1 (399), XRCC4-Intron 3, XRCC4 (1394) Gene Polymorphisms Polymorphisms of DNA Repair Genes in CML
1079PDF: 419HTML: 239 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2209PDF: 1037HTML: 1981Characteristic of study group: 196 -
ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
1359PDF: 753HTML: 942 -
DETECTION OF ANTINUCLEAR ANTIBODIES TARGETING INTRACELLULAR SIGNAL TRANSDUCTION, METABOLISM, APOPTOTIC PROCESSES AND CELL DEATH IN CRITICAL COVID-19 PATIENTS
1293PDF: 953HTML: 282Suppl. Figure: 182Suppl. Tables: 203 -
ASSESSMENT OF CONGENITAL NEUTROPENIA IN CHILDREN: COMMON CLINICAL SCENERIES AND CLUES FOR MANAGEMENT Assessment of congenital neutropenia in children
1972PDF: 1118HTML: 614 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
981PDF: 1158Suppl. Files: 144HTML: 66 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2160PDF: 1998HTML: 169 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2572PDF: 797HTML: 5207 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2250PDF: 1812HTML: 140 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3530PDF: 2394HTML: 1454 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3364PDF: 1288HTML: 1861Fig.1: 198Fig. 2: 203 -
IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
2207PDF: 957HTML: 1889 -
A CRITICAL HISTORY OF CHRONIC MYELOID LEUKEMIA
3224PDF: 1329HTML: 4128 -
ON THE VERSATILITY OF VON WILLEBRAND FACTOR
2778PDF: 1112HTML: 11215 -
A STUDY ON THE EXPRESSION OF BCR-ABL TRANSCRIPT IN MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL) CASES USING THE REVERSE TRANSCRIPTASE POLYMERASE REACTION ASSAY (RT-PCR) AND ITS CORRELATION WITH HEMATOLOGICAL REMISSION STATUS POST INITIAL INDUCTION THERAPY
1339PDF: 811HTML: 5032INSTITUTE PUBLICATION COMMITTEE APPROVAL: 159 -
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a case report and review of ABL kinase involvement in viral infection CML and COVID-19
3248PDF: 1525HTML: 415 -
DISSEMINATED HISTOPLASMOSIS AS AIDS PRESENTATION. CASE REPORT AND COMPREHENSIVE REVIEW OF CURRENT LITERATURE
3660PDF: 1279HTML: 725Figure 2: 449Figure 1: 3114 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1025PDF: 1148Suppl. Files: 569HTML: 82 -
FAMILIAL MEDITERRANEAN FEVER AND HYPERCOAGULABILITY
1200PDF: 710HTML: 1230 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
716PDF: 463HTML: 6263 -
The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review COVID-19 in Multiple Myeloma patients
961PDF: 357HTML: 188 -
TIMING FOR STEP-DOWN THERAPY OF CANDIDEMIA IN NON-NEUTROPENIC PATIENTS: AN INTERNATIONAL MULTI-CENTER STUDY Stepdown Therapy of Candidemia
2041PDF: 636HTML: 260 -
-
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1321PDF: 814HTML: 126 -
APPROPRIATE DURATION OF INTRAVENOUS TREATMENT OF CANDIDEMIA AND TIMING OF STEP DOWN TO ORAL THERAPY IN NON-NEUTROPENIC PATIENTS
2768PDF: 1011HTML: 360Preferred Reviewers: 203







